Integer Holdings Co. (NYSE:ITGR) Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA reduced its position in Integer Holdings Co. (NYSE:ITGR) by 12.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 257,925 shares of the medical equipment provider’s stock after selling 38,060 shares during the quarter. Pictet Asset Management Holding SA owned about 0.77% of Integer worth $34,180,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. New Age Alpha Advisors LLC acquired a new stake in shares of Integer during the fourth quarter worth about $249,000. Loomis Sayles & Co. L P lifted its position in Integer by 3.8% during the 4th quarter. Loomis Sayles & Co. L P now owns 558,715 shares of the medical equipment provider’s stock worth $74,041,000 after acquiring an additional 20,688 shares during the period. Artisan Partners Limited Partnership purchased a new position in shares of Integer in the 4th quarter valued at approximately $22,775,000. Zions Bancorporation N.A. increased its holdings in shares of Integer by 19.4% in the fourth quarter. Zions Bancorporation N.A. now owns 31,413 shares of the medical equipment provider’s stock valued at $4,163,000 after purchasing an additional 5,095 shares during the period. Finally, EntryPoint Capital LLC purchased a new stake in shares of Integer during the fourth quarter worth approximately $435,000. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

Integer Stock Performance

NYSE ITGR opened at $117.09 on Monday. The business has a 50 day moving average price of $130.47 and a 200 day moving average price of $132.09. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. The company has a market capitalization of $3.94 billion, a P/E ratio of 34.85, a PEG ratio of 1.72 and a beta of 1.24. Integer Holdings Co. has a 1-year low of $107.11 and a 1-year high of $146.36.

Integer (NYSE:ITGR) last released its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The firm had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million. Sell-side analysts expect that Integer Holdings Co. will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Citigroup lifted their price objective on shares of Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. KeyCorp boosted their price target on shares of Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Wells Fargo & Company restated an “overweight” rating and issued a $160.00 price objective on shares of Integer in a research report on Tuesday, December 3rd. Benchmark boosted their target price on Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Finally, Raymond James started coverage on Integer in a report on Friday. They issued an “outperform” rating and a $145.00 price target for the company. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Integer has an average rating of “Moderate Buy” and a consensus target price of $148.56.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.